LOS ANGELES--(BUSINESS WIRE)--Genesis Biopharma, Inc. (OTC/BB: GNBP), a biotechnology company developing targeted cellular immunotherapies for the treatment of cancer, today announced receipt of meeting minutes from the U.S. Food and Drug Administration (FDA) regarding a pre-Investigational New Drug (IND) application submission meeting for Contego™ held on August 23, 2012.
